Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2023 | The impact of novel targeted & immune therapies in leukemia

Norbert-Claude Gorin • 23 Apr 2023
EBMT 2023
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia Antibodies Azacitidine CAR-T Venetoclax

Norbert-Claude Gorin, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, comments on the advent of novel targeted and immune therapies in the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (AML), highlighting their impact on stem cell transplantation (SCT). This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Norbert-Claude Gorin

1:08
The progress of the EBMT & key ongoing projects
Norbert-Claude Gorin • 23 Apr 2023
1:23
Indications for autologous stem cell transplantation in AML
Norbert-Claude Gorin • 23 Apr 2023
1:39
The evolution of stem cell transplantation
Norbert-Claude Gorin • 23 Apr 2023
1:13
Outcomes following FD & NFD related donor haplo transplantation for patients with acute leukemias
Norbert-Claude Gorin • 23 Apr 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals